Before asking whether TB-500 works, ask what TB-500 actually is. Research on a larger peptide called thymosin beta-4 is often discussed alongside research on one of its shorter fragments, as if they were the same thing. They are related, but they are not automatically the same substance. Once the name of a molecule blurs, everything built on it, from mechanism to human evidence to safety, becomes harder to judge.
What is thymosin beta-4?
Thymosin beta-4 is a naturally occurring peptide of 43 amino acids, found in nearly all human cells. Its main job is to hold on to actin, a protein that forms part of the cell's internal skeleton, which controls how quickly a cell can reshape itself and move. That is why researchers link it to cell migration and tissue repair. In a laboratory study, it made human blood vessel lining cells migrate four to six times more in a standard assay In vitro 1.
That was an experiment on cells, not a treatment trial in people, and it shows both the interest and the limits. Repair is not one action. Cells respond to damage, move into the area and help rebuild it, and a molecule that influences one step can be scientifically important. That does not mean adding more of it will reliably improve every kind of injury. Being part of the repair process and being an effective treatment for damaged tissue are different claims.
What is the TB-500 fragment?
In 2012, researchers analysing a product sold as TB-500 identified Ac-LKKTETQ: an acetylated seven amino acid segment of thymosin beta-4, not the whole peptide 2. The US FDA's safety listing also names it separately, as the thymosin beta-4 fragment LKKTETQ, also known as TB-500.
You do not need to remember the sequence. What matters is that it identifies a particular chemical. A fragment may keep some of the activity of its parent molecule, or it may behave quite differently, and either possibility has to be tested. Cutting a section out of a molecule does not keep every property of the original, just as a page torn from an instruction manual may not contain the instructions you need. Coming from an interesting peptide is a reason to study the fragment, not permission to borrow the parent's evidence.
Does every product called TB-500 contain that fragment?
A label cannot tell you. The 2012 study identified what was in the material it tested, and that should not be stretched into a claim about every product sold under the same name. For scientific purposes the details that count are the actual sequence, any chemical modifications and the preparation used. That is why a good article does not slide between "TB-500", "thymosin beta-4" and "thymosin beta-4 fragment" without saying which it means. When checking a product claim against a research paper, molecular identity is the first checkpoint.
What did the early wound healing research show?
A well known 1999 experiment tested full length thymosin beta-4 on skin wounds in rats Animal 3. Treated wounds healed over faster, by 42% at day 4 and up to 61% at day 7, contracted more, and showed more collagen and new blood vessel growth.
That is a genuine positive preclinical result. It did not test a human sports injury, and it did not test a TB-500 product. A fair summary is that full length thymosin beta-4 improved specified outcomes in a rat skin wound model. "TB-500 is proven to repair injured human tendons" changes the molecule, the species, the injury and the outcome all at once.
Have there been human thymosin beta-4 studies?
Yes, and it would be wrong to call all thymosin beta-4 research animal or laboratory work. Most of the human work used RGN-259, a pharmaceutical eye drop containing synthetic thymosin beta-4, for conditions affecting the surface of the eye Human.
The results need careful reporting. A small phase 2 trial in severe dry eye, with nine patients, was positive 4. The large phase 3 dry eye trial, ARISE-3 with 700 participants, did not meet its primary outcome measures, according to the developer 5 6. In SEER-1, a small trial in neurotrophic keratopathy, a condition where the cornea fails to heal, 6 of 10 people on RGN-259 healed completely at four weeks against 1 of 8 on placebo, but that primary comparison fell short of statistical significance; a secondary measure, healing without recurrence by day 43, did reach it 7. Earlier phase 2 work in venous leg ulcers suggested a possible signal at one dose without demonstrating efficacy 8.
That is more informative than either "human trials prove it works" or "there is no human research". The research exists, and its less favourable results belong in the account.
Why primary and secondary outcomes matter
A clinical trial decides in advance what its central question is, the primary outcome, and may collect many secondary measurements alongside. If the main test shows no convincing difference, favourable secondary results can still be worth following up. They should not quietly replace the original question once the results are in.
Imagine testing whether a new teaching method improves exam scores. If scores do not improve but pupils say they enjoy lessons more, that is useful to know. It does not mean the exam score claim succeeded. The same applies to peptide trials: a fair summary says what the trial was designed to show and whether it showed it.
Why an eye drop study does not prove tendon repair
Suppose a thymosin beta-4 eye drop eventually shows a clear benefit for an eye condition. That would matter for that condition and that preparation. It would not show that injecting a fragment helps an Achilles injury. Is it the same molecule? Is the exposure comparable? Is the biological problem similar? Does the new route bring new risks? Does the treatment improve the relevant outcome? These questions decide what an experiment can tell you, so "human evidence" is not a stamp that can be applied to every proposed use of a related substance.
Has the TB-500 fragment itself been researched?
Yes, though not clinically. A 2024 study measured TB-500 and its breakdown products in the laboratory and in rats, and screened them for wound healing activity in cell tests In vitro Animal 9. Only one breakdown product, Ac-LKKTE, showed significant wound healing activity; TB-500 itself did not, and the authors suggest earlier reported effects may come from that metabolite.
That is a neat illustration of the whole problem. Even the fragment and its own breakdown products behave differently. Work like this answers early development questions, such as what is present, how to detect it and whether any biological effect is worth pursuing. A clinical programme would still need to show meaningful benefit and acceptable risk in the people it is meant for.
How evidence gets transferred by accident
The mistake usually follows a pattern. A researcher studies full length thymosin beta-4. A summary calls it a repair peptide. Another summary introduces TB-500 as if it were simply another name for the same thing. Eventually the original result sits beside a claim about a fragment or a blend. Each step reads more easily and says less precisely. Five checks keep the chain intact:
| Checkpoint | Question to ask |
|---|---|
| Molecule | Was it full length thymosin beta-4 or a named fragment? |
| Setting | Was the work in cells, animals or people? |
| Preparation | Was it an eye drop, a laboratory reagent or something else? |
| Condition | What problem was actually studied? |
| Outcome | What improved, and was it the study's main outcome? |
This is a reading framework, not a demand that every reader becomes a chemist. It shows when a citation is relevant to the claim beside it.
What can an identity test prove?
An analytical test can establish what was in the sample tested, which is why the 2012 identification study matters. It cannot show that the substance treats anything, or that every route or preparation is safe. "The compound was verified" and "the treatment is clinically validated" should never be used as if they meant the same thing.
Safety and sporting rules
For the fragment, the FDA has said it has not identified any human exposure data, and it has raised concerns about immune reactions linked to clumping and impurities 10. Its briefing for the July 2026 compounding advisory committee repeated the absence of human data 11. The fragment has since been moved off the FDA's category 2 safety list because its nomination was withdrawn, which is a procedural step, not a finding of safety. None of this is a full safety assessment of every thymosin beta-4 preparation. The eye drop trials, which gave hundreds of people topical thymosin beta-4, reported it as well tolerated; no trial has studied repeated injection.
For athletes, the 2026 WADA Prohibited List bans thymosin beta-4 and its derivatives, naming TB-500, at all times under section S2.3 12. Safety, anti doping status and clinical effect are three different questions, and none settles the others.
TB-500 (thymosin beta-4)
Mixed evidenceTissue repair · 10 cited studies
Genuine randomised, placebo controlled Phase 2 and Phase 3 trials exist in venous ulcers, pressure ulcers, dry eye and myocardial infarction, involving well over a thousand registered participants in total, but the large ophthalmic programme has not delivered a published primary endpoint success and no regulator has approved the peptide for any indication.
UK status. No MHRA marketing authorisation for any thymosin beta-4 product.
The BioRx conclusion
The central problem with TB-500 is not that every claim about it is invented. It is that research on different substances and different uses gets bundled together. Full length thymosin beta-4 has genuine biological and clinical research behind it. The fragment sold as TB-500 has to be judged on its own identity and its own evidence. Before accepting a TB-500 claim, check that the cited study investigated the same thing. That one check can change the meaning of an entire article, product description or comparison.
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 has 43 amino acids. A product sold as TB-500 was found to contain a seven amino acid fragment of it, and the FDA lists the fragment separately.
Has TB-500 been tested in humans?
No clinical trial of the TB-500 fragment has been published. The human trials, mostly in eye disease, used a pharmaceutical form of full length thymosin beta-4.
Did the thymosin beta-4 trials work?
Not cleanly. A small dry eye trial was positive, but the large phase 3 dry eye trial did not meet its primary outcomes, and a small neurotrophic keratopathy trial missed statistical significance on its primary comparison.
Is TB-500 banned in sport?
Yes. The WADA Prohibited List bans thymosin beta-4 and its derivatives, including TB-500, at all times.
References
Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.
- Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J 1997;11:474-481
- Esposito S et al. (2012). Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis.PubMed · DOI · View study in BioRx
- Malinda KM et al. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology.PubMed · DOI · View study in BioRx
- Sosne G, Dunn SP, Kim C (2015). Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
- ReGenTree, LLC (sponsor) (2019). Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3. ClinicalTrials.gov registry record.ClinicalTrials.gov · View study in BioRx
- RegeneRx, topline results of the ARISE-3 dry eye trial, 18 March 2021
- Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S (2022). 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
- Guarnera G et al. (2010). The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
- Rahaman KA et al. (2024). Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B.PubMed · DOI · View study in BioRx
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks
- FDA, Pharmacy Compounding Advisory Committee briefing on the thymosin beta-4 fragment, July 2026
- WADA, 2026 Prohibited List
